Technical Analysis for BLTE - Belite Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Doji - Bearish? | Reversal | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| 50 DMA Support | Bullish | -0.16% | |
| Wide Bands | Range Expansion | -0.16% | |
| Overbought Stochastic | Strength | -0.16% | |
| 50 DMA Support | Bullish | 0.91% | |
| Hammer Candlestick | Bullish | 0.91% | |
| Wide Bands | Range Expansion | 0.91% | |
| Overbought Stochastic | Strength | 0.91% | |
| NR7 | Range Contraction | 1.68% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 5 hours ago |
| 10 DMA Resistance | about 5 hours ago |
| Possible Inside Day | about 6 hours ago |
| 60 Minute Opening Range Breakout | about 7 hours ago |
| Down 3% | about 7 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/08/2024
Belite Bio, Inc. Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Diabetes Drug Development Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Oral Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 48.6 |
| 52 Week Low | 11.05 |
| Average Volume | 36,792 |
| 200-Day Moving Average | 38.64 |
| 50-Day Moving Average | 40.25 |
| 20-Day Moving Average | 40.46 |
| 10-Day Moving Average | 42.56 |
| Average True Range | 1.99 |
| RSI (14) | 57.98 |
| ADX | 20.57 |
| +DI | 15.91 |
| -DI | 22.58 |
| Chandelier Exit (Long, 3 ATRs) | 37.47 |
| Chandelier Exit (Short, 3 ATRs) | 36.99 |
| Upper Bollinger Bands | 46.14 |
| Lower Bollinger Band | 34.77 |
| Percent B (%b) | 0.67 |
| BandWidth | 28.11 |
| MACD Line | 0.85 |
| MACD Signal Line | 0.64 |
| MACD Histogram | 0.2133 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 44.86 | ||||
| Resistance 3 (R3) | 44.67 | 43.66 | 44.45 | ||
| Resistance 2 (R2) | 43.66 | 43.03 | 43.75 | 44.31 | |
| Resistance 1 (R1) | 43.02 | 42.64 | 42.52 | 43.21 | 44.17 |
| Pivot Point | 42.01 | 42.01 | 41.76 | 42.10 | 42.01 |
| Support 1 (S1) | 41.37 | 41.38 | 40.87 | 41.56 | 40.60 |
| Support 2 (S2) | 40.36 | 40.99 | 40.45 | 40.46 | |
| Support 3 (S3) | 39.72 | 40.36 | 40.32 | ||
| Support 4 (S4) | 39.91 |
